Clinical Drug Investigation

, Volume 9, Supplement 2, pp 58–60 | Cite as

Questions and Answers



Advanced Breast Cancer Daunorubicin Drug Invest Idarubicin Oral Administra 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Smith DB, Margison JM, Lucas SB, et al. Clinical pharmacology of oral and intravenous 4-demethoxydaunorubicin. Cancer Chemother Pharmacol 1987; 19: 138–42PubMedCrossRefGoogle Scholar
  2. 2.
    Zanette L, Zucchetti M, Freshi A, et al. Pharmacokinetics of 4-demethoxydaunorubicin in cancer patients. Cancer Chemother Pharmacol 1990; 25: 445–8PubMedCrossRefGoogle Scholar
  3. 3.
    Stewart DJ, Grewaal D, Green RM, et al. Bioavailability and pharmacology of oral idarubicin. Cancer Chemother Pharmacol 1991; 27: 308–14PubMedCrossRefGoogle Scholar
  4. 4.
    Camaggi CM, Strocchi E, Carisi P, et al. Idarubicin metabolism and pharmacokinetics after intravenous and oral administration in cancer patients. A cross-over study. Cancer Chemother Pharmacol 1992; 30: 307–16PubMedCrossRefGoogle Scholar
  5. 5.
    Hurteloup P, Armand JP, Schneider M, et al. Phase II trial of idarubicin (4-demethoxydaunorubicin) in advanced breast cancer. Eur J Cancer Clin Oncol 1989; 25: 423–8PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1995

Personalised recommendations